Appointments at Sproxil, Intercell and Evolva Holding – People on the move
Cambridge Major Laboratories (CML) has named Richard Proehl as vice president (VP) of manufacturing. Proehl last worked at Coviden where he was responsible for the company’s largest active pharmaceutical ingredient (API) production plant.
Paul Chang has joined the board of advisors at anti-counterfeiting firm Sproxil. Chang is global business strategy lead, emerging technologies at IBM Software Group and joined the company in 2004.
Merck Sharp & Dohme (MSD) has appointed Steve Warner as managing director of its Romanian subsidiary. Warner succeeds Agata Jakoncic who has been promoted to the regional level.
Thomas Lingelbach has been named CEO of Intercell AG after Gerd Zettlmeissl resigned “to pursue other personal and professional interests”. Lingelbach joined Intercell as chief operating officer in 2006 and has been involved with manufacturing and product development at Novartis.
Evolva Holding SA has hired Norbert Bender as chief medical officer. Bender has worked in biopharm companies, including Knoll and ViroLogik, for more than 20 years.
Yanliang Song has joined Global Pharm as VP in charge of operations in a three year deal. Song has 15 years of pharma experience and has served as general manager at a number of companies.
Aceto has elected Salvatore Guccione to its board of directors. Guccione is an operating partner at Arsenal Capital Partners and has previously worked at WIL Research Laboratories, Cambrex and International Speciality Products.
Steve Tullman has been hired as chairman and CEO of Yaupon Therapeutics. Tullman was president and CEO of Ception Therapeutics, which Cephalon bought last year, and is the current chairman of Vicept Therapeutics.
